OSCIENT PHARMACEUTICALS CORPORATION AGREES TO ACQUIRE CARDIOVASCULAR THERAPY ANTARA 130 MG (FENOFIBRATE) CAPSULES FROM RELIANT PHARMACEUTICALS, INC. FOR ABOUT $78 MILLION

Oscient Pharmaceuticals has agreed to acquire U.S. rights to the cardiovascular product ANTARA 130 mg (fenofibrate) capsules from Reliant Pharmaceuticals. ANTARA is part of the $1 billion fenofibrate market and will be commercialized by Oscient's national sales force, which currently is marketing FACTIVE (gemifloxacin mesylate) tablets and TESTIM® 1% testosterone gel, upon closing.
BioSpace